Proteins and Peptides

05 May 2021 Carmot Therapeutics Announces Investigational New Drug (IND) Clearance for CT-868, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Overweight and Obese Patients with Type 2 Diabetes
28 Apr 2021 OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain
28 Apr 2021 Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
27 Apr 2021 Alkermes Initiates ARTISTRY-6 Trial of Nemvaleukin Alfa Monotherapy in Patients With Melanoma
26 Apr 2021 Neoleukin Therapeutics Announces Clearance to Proceed with NL-201 Phase 1 Clinical Trial in the United States
23 Apr 2021 UCB’s zilucoplan shows no relevant effect in immune-mediated necrotizing myopathy (IMNM)
22 Apr 2021 Pharming announces enrolment of first patient in multicentre Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction
14 Apr 2021 Aquavit to Introduce A New Botulinum Toxin (DTX-021)
13 Apr 2021 Peptilogics Announces Successful Completion of Phase 1 Clinical Trial of PLG0206, a First-in-Class Anti-Infective Peptide Therapy
13 Apr 2021 Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
12 Apr 2021 Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)
12 Apr 2021 Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting
12 Apr 2021 Molecular Partners Shares New Preclinical Data from its AML-Focused CD3 T-Cell Engager Program, CD40 Product Candidate MP0317, and Other Novel Immuno-oncology Approaches at AACR
11 Apr 2021 Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities
06 Apr 2021 Molecular Templates to Prioritize Next-Generation ETB Candidates
06 Apr 2021 AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia
06 Apr 2021 Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients
02 Apr 2021 Evive Biotech Submits Biologics License Application to US FDA for Ryzneuta™
30 Mar 2021 D&D Pharmatech Announces First Patient Dosed in Phase 1 Clinical Trial of DD01 in Obese Patients with Diabetes and NAFLD
27 Mar 2021 Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12–17 years
24 Mar 2021 Asher Bio Launches with $55 Million Series A Financing Led by Third Rock Ventures to Discover and Develop Highly Specific Immunotherapies Using a Novel Technology Platform
23 Mar 2021 JCR Pharmaceuticals Announces Approval of IZCARGO® (Pabinafusp Alfa) for Treatment of MPS II (Hunter Syndrome) in Japan
23 Mar 2021 Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
23 Mar 2021 Novo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
23 Mar 2021 Zealand Pharma Announces FDA Approval of Zegalogue (dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with Diabetes

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up